KnowBe4 Report Reveals Security Training Reduces Global Phishing Click Rates by 86%
KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today launched its “Phishing by Industry Benchmarking Report 2025” which measures an organization’s Phish-prone™ Percentage (PPP) — the percentage of employees likely to fall for social engineering or phishing attacks, indicating the organization’s overall susceptibility to phishing threats. This year’s report found a global average baseline PPP of 33.1%, meaning a third of employees interact with phishing simulations before taking part in best-practice security awareness training (SAT).
The data underscores the significant impact of SAT in mitigating risk. The rapid decline in the global PPP following the implementation of training — falling by 40% in just three months and by a total of 86% after 12 months — demonstrates that ongoing, effective training leads to lasting behavior change and a substantial reduction in vulnerability to cybersecurity threats. This highlights the critical role of continuous education in building a stronger security culture within organizations, even in as little as three months.
KnowBe4 analyzed 67.7 million phishing simulations globally, across 14.5 million users from 62.4 thousand organizations. The baseline PPP (33.1%) reflects an organization’s susceptibility to phishing before any KnowBe4 training. Employees then undergo KnowBe4’s SAT, and the PPP is recalculated after 90 days and again after one year-plus of ongoing training to quantify the program’s effectiveness.
Other Key Findings from the Phishing By Industry Benchmarking Report:
- Globally, the top three most at-risk industries with the highest baseline PPP were Healthcare & Pharmaceuticals (41.9%), Insurance (39.2%), and Retail & Wholesale (36.5%).
- Larger organizations faced a higher initial phishing risk, with those having 10,000+ employees showing a global baseline PPP of 40.5%, compared to 24.6% for organizations with 1-250 employees.
- In organizations of 1,000-9,999 employees, three sectors all achieved PPP improvement rates of 91% after 12 months of on-going training: Healthcare & Pharmaceuticals, Hospitality and Legal.
- Across the different regions, the highest baseline PPPs were found in South America (39.1%), North America (37.1%), and Australia and New Zealand (36.8%).
“The data speaks for itself — security awareness training truly makes a difference,” said Stu Sjouwerman, CEO of KnowBe4. “From 2024 to 2025, the general trend has remained fairly consistent — around one-third of employees click on a simulated phishing link before taking part in training. However, the data shows a slight improvement in 2025. Within a year, we’ve seen a 3.5% decrease in the global baseline PPP, highlighting a positive shift in overall security awareness worldwide. However, there is still significant progress to be made in fully addressing phishing risks. By consistently prioritizing relevant and engaging training, combined with simulated phishing, organizations can strengthen their human risk management strategies and better protect against phishing to improve overall security culture.”
To download a copy of the Phishing by Industry Benchmarking Report 2025, visit here.
About KnowBe4
KnowBe4 empowers workforces to make smarter security decisions every day. Trusted by over 70,000 organizations worldwide, KnowBe4 helps to strengthen security culture and manage human risk. KnowBe4 offers a comprehensive AI-driven ‘best-of-suite’ platform for Human Risk Management, creating an adaptive defense layer that fortifies user behavior against the latest cybersecurity threats. The HRM+ platform includes modules for awareness & compliance training, cloud email security, real-time coaching, crowdsourced anti-phishing, AI Defense Agents, and more. As the only global security platform of its kind, KnowBe4 utilizes personalized and relevant cybersecurity protection content, tools and techniques to mobilize workforces to transform from the largest attack surface to an organization’s biggest asset.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250513295204/en/
Contacts
Media Contact:
Kathy Wattman
SVP of Public Relations
kathyw@knowbe4.com
727-474-9950
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom